February 1, 2021
ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
TB Alliance to leverage ZebiAI’s platform to discover novel probe compounds for important tuberculosis targets, with options for drug discovery January 28, 2021
New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010
Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development December 14, 2020
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
Study seeks to further develop a new compound to treat patients with tuberculosis December 8, 2020
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
October 30, 2020
TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent
October 23, 2020
TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB cases October 14, 2020
With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
August 4, 2020
Dr. Mel Spigelman Named in Fast Company’s Annual List of the Most Creative People in Business
August 3, 2020